サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1668104

卵胞刺激ホルモン市場- 世界の産業規模、動向、機会、予測、タイプ別、用途別、地域別、競合別、2020～2030年

Follicle Stimulating Hormone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application (Infertility Treatment, Assisted Reproductive Application, Others), By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

卵胞刺激ホルモン市場- 世界の産業規模、動向、機会、予測、タイプ別、用途別、地域別、競合別、2020～2030年
出版日: 2025年02月28日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

卵胞刺激ホルモンの世界市場規模は2024年に18億6,000万米ドルで、予測期間中のCAGRは5.84%で2030年には22億1,000万米ドルに達すると予測されています。

世界の卵胞刺激ホルモン（FSH）市場は、数十年にわたり医療産業において重要な役割を担ってきました。FSHはヒトの生殖に重要な役割を果たす重要なホルモンであり、不妊治療やホルモン補充療法の基本要素となっています。世界人口の高齢化が進み、不妊率が上昇し、ホルモン関連疾患に対する意識が高まるにつれ、FSH市場は著しい成長と技術革新を目の当たりにしています。下垂体前葉で産生される卵胞刺激ホルモンは、男女ともに生殖器系の重要な調節因子です。女性の場合、FSHは卵巣卵胞の成長を刺激し、排卵を誘発します。男性では、精巣を刺激して精子を産生させています。FSHレベルの調節障害は、不妊、月経不順、ホルモンバランスの乱れなど、生殖に関するさまざまな健康問題を引き起こす可能性があります。ポイントオブケア（POC）検査機器は、迅速かつ現場での診断を可能にすることで、医療に革命をもたらしました。FSH市場では、POC機器によって医療提供者がFSH検査結果を即座に得ることが可能になり、患者の待ち時間が短縮され、より迅速な治療方針の決定が容易になりました。これは特に不妊治療クリニックや生殖医療センターにとって有益です。

市場概要
予測期間 2026～2030年
市場規模：2024年 18億6,000万米ドル
市場規模：2030年 22億1,000万米ドル
CAGR：2025～2030年 5.84%
急成長セグメント 不妊治療
最大市場 北米

世界的に高齢化が進み、子作りを遅らせるために不妊治療を希望する女性が増加しています。このような人口動態により、FSHを用いた不妊治療に対する需要が急増しています。医療情報発信の進歩により、不妊問題やホルモン関連疾患に対する意識が高まり、医療支援を求める人が増えていることが、FSH市場の成長を後押ししています。バイオテクノロジーや医薬品のセグメントにおける技術革新により、より効果的なFSH製品や治療法が開発され、より改善された結果や副作用の減少がもたらされています。多くの国の政府は、生殖補助医療技術やホルモン補充療法を支援する措置を講じています。これには、治療への助成、規制障壁の緩和、このセグメントの研究への資金援助などが含まれます。

市場促進要因

不妊症の有病率の増加が世界の卵胞刺激ホルモン市場を牽引

主要市場課題

不妊治療費の高騰

主要市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の卵胞刺激ホルモン市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別（組換えFSH、尿中FSH）
    • 用途別（不妊治療、生殖補助医療（ART）、その他）
    • 地域別
    • 企業別（2024年）
  • 市場マップ

第6章 北米の卵胞刺激ホルモン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の卵胞刺激ホルモン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋の卵胞刺激ホルモン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の卵胞刺激ホルモン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの卵胞刺激ホルモン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収（該当する場合）
  • 製品の発売（該当する場合）

第13章 ポーターのファイブフォース分析

  • 産業内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Midas Pharma GmbH
  • Creative BioMart inc.
  • Genpharm Services
  • Merck KgAa
  • Livzon Pharmaceutical Group Inc
  • Shanghai Techwell Biopharmaceutical Co., Ltd
  • Medix Biochemica USA Inc.
  • Biogenix Inc.Pvt.Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 19204

Global Follicle Stimulating Hormone Market was valued at USD 1.86 Billion in 2024 and is expected to reach USD 2.21 Billion by 2030 with a CAGR of 5.84% during the forecast period. The global Follicle Stimulating Hormone (FSH) market has been a critical player in the healthcare industry for decades. FSH is a vital hormone that plays a significant role in human reproduction, making it a fundamental component of fertility treatments and hormone replacement therapy. As the world's population continues to age, infertility rates rise, and awareness about hormone-related disorders increases, the FSH market has witnessed significant growth and innovation. Follicle Stimulating Hormone, produced by the anterior pituitary gland, is a key regulator of the reproductive system in both men and women. In females, FSH stimulates the growth of ovarian follicles and triggers ovulation. In males, it stimulates the testes to produce sperm. Dysregulation of FSH levels can lead to various reproductive health issues, including infertility, irregular menstrual cycles, and hormone imbalances. Point-of-Care (POC) Testing devices have revolutionized healthcare by enabling rapid and on-site diagnostics. In the FSH market, POC devices have made it possible for healthcare providers to obtain immediate FSH test results, reducing patient wait times and facilitating faster treatment decisions. This is particularly beneficial for fertility clinics and reproductive health centers.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.86 Billion
Market Size 2030USD 2.21 Billion
CAGR 2025-20305.84%
Fastest Growing SegmentInfertility Treatment
Largest MarketNorth America

The global population is aging, with an increasing number of women seeking fertility treatments as they delay parenthood. This demographic trend has led to a surge in demand for FSH-based therapies to enhance fertility. Increasing awareness about fertility issues and hormone-related disorders, driven by advancements in healthcare information dissemination, has encouraged more people to seek medical assistance, thereby driving FSH market growth. Innovations in the field of biotechnology and pharmaceuticals have led to the development of more effective FSH products and therapies, offering improved results and fewer side effects. Governments in many countries have taken steps to support assisted reproductive technologies and hormone replacement therapies. This includes subsidizing treatments, reducing regulatory barriers, and funding research in the field.

Key Market Drivers

Increasing Prevalence of Infertility is Driving the Global Follicle Stimulating Hormone Market

Infertility has become a growing concern worldwide, affecting millions of couples who dream of starting a family. In recent years, the prevalence of infertility has been on the rise, contributing to the expansion of the global Follicle Stimulating Hormone (FSH) market. As per the World Health Organization's data updated in April 2023, approximately 1 in 6 adults globally are affected by infertility. FSH, a crucial hormone for reproductive health, has gained prominence as a key player in fertility treatments. Infertility is a medical condition defined by the inability to conceive after a year of regular, unprotected sexual intercourse. It can result from various factors, including hormonal imbalances, age-related declines in fertility, structural issues, and lifestyle factors. Changing societal trends, including delayed marriages and career-focused lifestyles, have led many couples to postpone starting a family until later in life. Unfortunately, female fertility declines with age, making conception more challenging. Environmental toxins, pollutants, and the exposure to endocrine-disrupting chemicals have been linked to fertility issues. These factors can disrupt hormonal balance, including FSH levels, crucial for healthy reproductive function. The modern lifestyle, characterized by high stress levels, sedentary habits, and poor dietary choices, can negatively impact fertility. Stress hormones can interfere with reproductive hormones, including FSH. According to the

Key Market Challenges

High Cost of Fertility Treatments

One of the major challenges facing the Global Follicle Stimulating Hormone (FSH) Market is the high cost of fertility treatments, which often limits accessibility for a significant portion of the population. While FSH is essential for assisted reproductive technologies (ART) like in vitro fertilization (IVF), the overall cost of these procedures can be prohibitively expensive, particularly in low- and middle-income countries. The cost of FSH injections, along with the additional expenses associated with IVF cycles, such as diagnostic tests, consultations, and hospital stays, creates financial barriers for many individuals seeking fertility treatments. Multiple rounds of IVF may be required for success, further escalating costs. Despite the growing availability of fertility insurance in some regions, many patients still struggle with the affordability of these therapies. This economic challenge hinders market growth, as the high cost limits the number of people who can access and afford treatment. To overcome this barrier, there is a need for more affordable treatment options, government subsidies, and broader insurance coverage to make fertility treatments more accessible globally.

Key Market Trends

Technological Advancements

The field of medicine and healthcare is continuously evolving, with technological advancements playing a pivotal role in shaping the future of diagnostics and treatments. One such area experiencing significant growth is the global Follicle Stimulating Hormone (FSH) market. FSH is a critical hormone responsible for regulating the reproductive system in both men and women. The market for FSH has been witnessing remarkable growth, largely driven by advancements in technology and a growing demand for fertility treatments and diagnostic tools. One of the key technological advancements in the FSH market is the development of highly sensitive assays for FSH measurement. Traditional FSH assays were relatively less precise and had limitations in detecting low levels of the hormone. However, modern immunoassays and automated platforms have greatly improved the accuracy and sensitivity of FSH testing. This has made it easier for healthcare professionals to diagnose and monitor reproductive disorders with precision. Advances in microfluidics and biosensor technologies have led to the development of user-friendly home fertility testing kits. These kits allow individuals to monitor their FSH levels at home, providing valuable insights into their reproductive health. Such technology empowers individuals to take control of their fertility and seek medical intervention when necessary.

Key Market Players

  • Merck KgAa
  • Creative BioMart inc.
  • Midas Pharma GmbH
  • Genpharm Services
  • Livzon Pharmaceutical Group Inc
  • Shanghai Techwell Biopharmaceutical Co., Ltd
  • Medix Biochemica USA Inc.
  • Biogenix Inc.Pvt.Ltd.

Report Scope:

In this report, the Global Follicle Stimulating Hormone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Follicle Stimulating Hormone Market, By Type:

  • Recombinant FSH
  • Urinary FSH

Follicle Stimulating Hormone Market, By Application:

  • Infertility Treatment
  • Assisted Reproductive Application (ART)
  • Others

Follicle Stimulating Hormone Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Follicle Stimulating Hormone Market.

Available Customizations:

Global Follicle Stimulating Hormone market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Follicle Stimulating Hormone Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Recombinant FSH, Urinary FSH)
    • 5.2.2. By Application (Infertility Treatment, Assisted Reproductive Application (ART), Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Follicle Stimulating Hormone Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Follicle Stimulating Hormone Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Follicle Stimulating Hormone Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Follicle Stimulating Hormone Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Follicle Stimulating Hormone Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Follicle Stimulating Hormone Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. United Kingdom Follicle Stimulating Hormone Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Italy Follicle Stimulating Hormone Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. France Follicle Stimulating Hormone Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Follicle Stimulating Hormone Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia-Pacific Follicle Stimulating Hormone Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Follicle Stimulating Hormone Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Follicle Stimulating Hormone Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Follicle Stimulating Hormone Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Follicle Stimulating Hormone Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Follicle Stimulating Hormone Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. South America Follicle Stimulating Hormone Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Follicle Stimulating Hormone Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Follicle Stimulating Hormone Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Follicle Stimulating Hormone Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. Middle East and Africa Follicle Stimulating Hormone Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Follicle Stimulating Hormone Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Follicle Stimulating Hormone Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Follicle Stimulating Hormone Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Midas Pharma GmbH
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Creative BioMart inc.
  • 14.3. Genpharm Services
  • 14.4. Merck KgAa
  • 14.5. Livzon Pharmaceutical Group Inc
  • 14.6. Shanghai Techwell Biopharmaceutical Co., Ltd
  • 14.7. Medix Biochemica USA Inc.
  • 14.8. Biogenix Inc.Pvt.Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer